Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 4Thoracic 3Gastrointestinal 3Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1

Conditions

Cholangiocarcinoma 10Gastrointestinal Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma 2Sarcoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Locally Advanced Unresectable Gastric Cancer 1Gastrointestinal Stromal Tumors 1Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel 1Endometrial Neoplasms 1Digestive System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 36Capecitabine 28Trastuzumab 23Paclitaxel 22Surveys and Questionnaires 20Cyclophosphamide 20Gemcitabine 18Docetaxel 18Carboplatin 15Nivolumab 14Methods 14Magnetic Resonance Spectroscopy 13Early Intervention, Educational 13Bevacizumab 13Interviews as Topic 12Blood Specimen Collection 12fludarabine 11Standard of Care 11Irinotecan 11olaparib 10durvalumab 10Specimen Handling 10Psychiatric Rehabilitation 10palbociclib 9aldesleukin 9Taxes 9Fulvestrant 9Fluorouracil 9Exercise 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Breast Neoplasms × pemigatinib × Gastrointestinal × Clear all
NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
30 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

NCT04591431 2023-10-03

ROME

Fondazione per la Medicina Personalizzata

Phase 2 Unknown
400 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡